FDA Accepts Mitsubishi Tanabe Pharma’s NDA Filing for Edaravone to Treat ALS
/Mitsubishi Tanabe Pharma has announced that the FDA has accepted their NDA filing for Edaravone to treat ALS. Read more about what this means for our PALS by clicking the link below.
http://www.mt-pharma.co.jp/e/release/nr/2016/pdf/e_MTPC160830_RC.pdf